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Summary Prodrugs can have the advantage over parent
drugs in increased activation and cellular uptake. The
multidrug ETC-L-FdUrd and the duplex drug ETC-FdUrd
are composed of two different monophosphate-nucleosides,
5-fluoro-2′deoxyuridine (FdUrd) and ethynylcytidine (ETC),
coupled via a glycerolipid or phosphodiester, respectively.
The aim of the study was to determine cytotoxicity levels and
mode of drug cleavage. Moreover, we determined whether a
liposomal formulation of ETC-L-FdUrd would improve
cytotoxic activity and/or cleavage. Drug effects/cleavage
were studied with standard radioactivity assays, HPLC and
LC-MS/MS in FM3A/0 mammary cancer cells and their
FdUrd resistant variants FM3A/TK−. ETC-FdUrd was active
(IC50 of 2.2 and 79 nM) in FM3A/0 and TK
− cells,
respectively. ETC-L-FdUrd was less active (IC50: 7 nM in
FM3A/0 vs 4500 nM in FM3A/TK−). Although the
liposomal formulation was less active than ETC-L-FdUrd
in FM3A/0 cells (IC50:19.3 nM), resistance due to thymidine
kinase (TK) deficiency was greatly reduced. The prodrugs
inhibited thymidylate synthase (TS) in FM3A/0 cells
(80–90%), but to a lower extent in FM3A/TK− (10–50%).
FdUMP was hardly detected in FM3A/TK− cells. Inhibition
of the transporters and nucleotidases/phosphatases resulted in
a reduction of cytotoxicity of ETC-FdUrd, indicating that this
drug was cleaved outside the cells to the monophosphates,
which was verified by the presence of FdUrd and ETC in the
medium. ETC-L-FdUrd and the liposomal formulation were
neither affected by transporter nor nucleotidase/phosphatase
inhibition, indicating circumvention of active transporters.
In vivo, ETC-FdUrd and ETC-L-FdURd were orally active.
ETC nucleotides accumulated in both tumor and liver
tissues. These formulations seem to be effective when a
lipophilic linker is used combined with a liposomal
formulation.
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Introduction
Of many chemotherapeutic agents that have been developed
in preclinical studies, only a fraction reaches the clinic. One
very successful anticancer drug is 5-fluorouracil (5-FU). The
introduction of 5-FU into the clinic has significantly improved
the treatment response and survival for cancer patients,
particularly in colon, head and neck and breast cancer.
However, important therapeutic limitations are a short
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biological half-life and the induction of resistance. Part of this
resistance can be circumvented by the use of 5-FU analogs
and/or prodrugs, such as 5-fluoro-2′deoxyuridine (FdUrd) [1],
5′-deoxy-5-fluorodeoxyuridine and ftorafur [2], a constituent
of the oral 5-FU formulations UFT and S-1 [3]. 5-FU
resistance mechanisms include increased thymidylate
synthase (TS) expression levels [4], and for FdUrd a lowered
thymidine kinase (TK) expression. Unsuccessful delivery of
the nucleoside analogs can be mediated by a decreased
cellular uptake by nucleoside transporters [5]. Therefore,
modifications of nucleoside analogs by introduction of a
lipid side-chain could improve cellular uptake, such as for
Ara-C [6]. Other (chemical) modifications are the addition of
a lipophilic chain to the monophosphorylated nucleoside
rather than to the nucleoside analog itself [7, 8]. This is the
so-called pronucleotide approach, which includes the SATE
and SGTE compounds. These types of pronucleotides have
demonstrated that it is possible to successfully deliver
nucleotides into the cells in vitro [9]. Thereby, both uptake
and the first activation step, mostly the rate-limiting, can be
bypassed. Another strategy to increase the activity of one drug
is to apply it in combination with other drugs [10].
Combination therapies are currently the standard for the
treatment of various types of cancer, examples are the
FOLFOX and FOLFIRI regimens as treatment against
colorectal cancer [11–13].
To combine the advantages of these three strategies: (1)
circumventing drug uptake by transporters, (2) bypassing the
first activation step and (3) combining two drugs to improve
their activity, combination-drugs have been developed. These
drugs are composed of two different single active drugs, such
as 5-FU and chloroethylnitrosourea (CNU) [14]. However,
such a drug can also be composed of two different active
nucleoside analogs, such as FdUrd and the novel 3′-C-
ethynylcytidine (ETC). FdUrd is the 5-FU deoxynucleoside
that can be directly monophosphorylated by TK to FdUMP.
5-FU acts by inhibition of TS by forming a stable ternary
complex with 5,10CH2-THF mediated by 5-FdUMP.
Furthermore, FdUTP can be incorporated into the DNA
[1]. ETC is a new anticancer ribonucleoside that can be
incorporated into the RNA after activation by specific
enzymes (e.g. uridine cytidine kinase, UCK), thereby
inducing cell death [7, 8]. ETC has shown preclinical
activity in lung, colon and breast cancer and is now under
investigation in phase I clinical trials [7, 15–17].
The multidrug tested in the present study is composed of
the mononucleotide of ETC, coupled with a glycerophos-
pholipid bridge to FdUrd (ETC-L-FdUrd). The duplex drug
is composed of the mononucleoside of ETC linked with a
phosphodiester to FdUrd (ETC-FdUrd) (Fig. 1). When
these drugs are enzymatically cleaved behind the phosphate
group, the mononucleotides (FdUMP or ETCMP) will be
released. Therefore, the specific activating enzymes TK and
UCK will be redundant and resistance due to deficiency in
these key enzymes can be overcome. The lipid group of the
multidrug may have the advantage to facilitate cell permeation
through passive diffusion or possibly via a vesicle mediated
uptake, bypassing the nucleoside transporter. When the drug
is inside the cell, specific enzymes can further activate it. For
another multidrug, AraC-L-FdUrd, a partial reversal of
resistance to one drug was found [18]. However, we
previously concluded that the efficacy of the two drugs was
too different in order to exert a cytotoxic effect of both drugs
[19]. Another strategy to increase drug uptake is by a
liposomal formulation, which has already shown promising
results with cytarabine and doxorubicin [20, 21]. To evaluate
whether a liposomal formulation could increase drug
activity, we tested the multidrug ETC-L-FdUrd in a
liposomal formulation [22].
The aim of this study was to compare the multi- and
duplex drug and the liposomal formulation of the multidrug
on cytotoxicity both in vitro and in vivo and to analyze
whether the drugs are cleaved in- or outside the cell and
which cleavage products are obtained.
Materials & methods
Chemicals
The investigated duplex drug ETC-FdUrd (3′-C-
Ethynylcytidylyl-(5′➔5′)-5-fluoro-2′-deoxyuridine) and the
multidrug, ETC-L-FdUrd (3′-C-Ethynylcytidylyl-(5′➔1)-2-
O-octadecyl-glycerylyl-(3➔5′)-5-fluoro-2′-deoxyuridine)
were synthesized by Prof. Dr. H. Schott [23]. FdUrd (5-fluoro-
2′-deoxyuridine) and alkaline phosphatase were purchased
from Sigma-Aldrich Chemicals (Zwijndrecht, The Neth-
erlands). [5-3H]-2′-deoxycytidine (3H-dCyd) and [6-3H]-
5-fluoro-2′-deoxyuridine-monophosphate (3H-FdUMP),
were obtained from Moravek Biochemicals Inc. (Brea,
CA, USA). All other chemicals used were of standard
quality and commercially available.
Cell culture
The murine breast cancer suspension cell lines FM3A/0 and
FM3A/TK− were a gift from Prof. Dr. J. Balzarini at the
Rega Institute (Leuven, Belgium) and Dr Seno (Japan) [24].
The original FM3A/TK− cells are deficient in cytosolic
TK1 and can not activate FdUrd. FM3A cells were cultured
in RPMI, supplemented with 10% heat inactivated FCS and
20 mM HEPES. The 5-FU resistant colon carcinoma cell
line HT29 was cultured in DMEM, supplemented with
10% heat inactivated FCS and 20 mM HEPES. All cells
were maintained in a humidified atmosphere at 37 °C
and 5% CO2.
Invest New Drugs (2011) 29:248–257 249
Drug cytotoxicity assays
Drug cytotoxicity in FM3A/0 and FM3A/TK− cells was
determined using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,
5-diphenyl tetrazolium bromide) assay for suspension cell
lines as described previously [25]. In brief, 10 000 cells/well
were seeded, after which drugs were added at increasing
concentrations. After 72 h of continuous drug exposure, 10 µl
MTT (5 mg/ml) was added to each well for 3 h at 37 °C.
Thereafter, formazan crystals were dissolved in 100 µL of
0.04 N HCl-isopropyl alcohol and the optical density (OD)
was measured at 495–540 nm. Drug cytotoxicity in HT-29
cells was determined using the sulphorhodamine B (SRB)-
assay as described previously [25]. Cells (7000/well) were
seeded, after which the drugs were added at increasing
concentrations. After 72 h of continuous drug exposure, cells
were fixed in trichloroacetic acid (TCA) and stained with SRB.
After diluting the SRB-dye in 150 µl 10 mM Tris-solution, the
OD was measured at 495–540 nm. IC50 values were defined
as the concentrations that correspond to a reduction of cell
growth by 50 % when compared to values of untreated
control cells and are given in means±SEM.
Drug cleavage
To determine intra- and extracellular drug cleavage, cells were
pre-treated with the equilibrative nucleoside transporter
inhibitor (ENT) dipyridamole (1 µM), the concentration that
was previously shown to prevent nucleoside entry [26] To
determine whether the drug is cleaved (outside the cell) into
a nucleotide and subsequently degraded to a nucleoside, cells
were also treated with a nucleotidase (2.5 mM α,
ß-methylene-ADP) and a phosphatase inhibitor (15 mM
2-glycerol-phosphate), at concentrations previously shown to
prevent nucleotidase or phosphatase mediated breakdown of
(fluorinated) pyrimidine analogues [27, 28]. The protection
factor was determined by dividing the growth of cells treated
with inhibitor(s) by the growth of cells treated without
inhibitor(s).
TS in situ activity assay
Inhibition of thymidylate synthase (TS) in intact FM3A/0
and FM3A/TK− cells was determined by measuring the
conversion of [3H]-dCyd to 3H2O, which is catalyzed by TS
as described previously [28, 29]. Briefly, 1×106 cells were
seeded and incubated with the different drugs for 22 h.
Subsequently, [3H]-dCyd (final concentration: 1 µM, specific
activity 4.9 Ci/mmol) was added to each sample for 2 h at
37 °C. Blanks consisted of culture medium only and as
controls untreated cells were used. The reaction was stopped
by adding TCA and unconverted [3H]-dCyd was removed
by activated charcoal. After centrifugation, the supernatant
was transferred to a liquid scintillation vial and counted.
FdUMP assay
The level of FdUMP accumulation was determined with an
isotope-dilution assay, based on the binding of [6-3H]-
FdUMP to L. casei TS [30, 31]. Cells (2x106) were
incubated for 24 h with 0.05 µM of the different drugs.
After the incubation period, samples were deproteinized by
TCA and neutralized. Cell extract (75 µl) was added to 10 µl
assay buffer (200 mM Tris, 100 mM sodium fluoride,
15 mM CMP, 20 mM β-mercaptoethanol, pH 7.4), 10 µl
6.4 mM folate (CH2-THF), 10 µl 0.01 µCi [6-
3H]-FdUMP
(specific activity of 53 mCi/mmol) and 10 µl 25 nM TS and
subsequently incubated at 30 °C for 2 h. The assay was
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ETC-5FdUrd ETC-L-5FdUrdFig. 1 Structural formulas
of the duplex drug ETC-FdUrd
(3’-C-Ethynylcytidylyl-(5’➔5’)-
5-fluoro-2’-deoxyuridine)
and the multidrug ETC-L-FdUrd
(3’-C-Ethynylcytidylyl-(5’➔1)-
2-O-octadecyl-glycerylyl-
(3➔5’)-5-fluoro2’-deoxyuridine)
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stopped by adding ice-cold 3% charcoal to each sample.
Samples were centrifuged for 15 min at 12000 rpm and
counted in Optima Gold liquid scintillation fluid in a liquid
scintillation counter (Packard Instrument B.V., Chemical
Operations, Groningen, The Netherlands).
HPLC analysis of nucleosides
To determine the total amount of extracellular nucleosides
(FdUrd and ETC), cells were exposed to 100 µM of the
drugs for 24 h. Since FM3A/TK− cells may accumulate less
active nucleosides, this higher concentration was chosen in
order to allow reliable measurement. After the drug
exposure, a sample was taken from the medium above the
cells (after centrifugation), which was extracted as
described for the FdUMP assay. HPLC-UV detection was
performed as described previously with the nucleoside
assay [32].
LC-MS/MS detection of ETC-nucleotides
To determine the total amount of intracellular mono- di- and
triphosphates of the ETC-nucleosides, cells were exposed to
100 µM of the drugs for 24 h, after which they were extracted
as described for the FdUMP assay. Thereafter, neutralized
extracts were treated with alkaline phosphatase and subse-
quently precipitated with ice cold isopropyl alcohol. After
centrifugation (21 000 g at 4 °C, 10 min), supernatants were
transferred to a new vial and evaporated via freeze drying. The
sample was reconstituted in ethyl acetate and back-extracted
with 50 µl water. After centrifugation (21 000 g at 4 °C), the
aqueous layer was transferred to a 96 well plate for LC-MS/
MS analysis (TSI-API3000 mass spectrometer) essentially as
described earlier for gemcitabine [33]. For ETC the molecular
ion [M+H]+ 268.2 was observed, fragmentation of this ion
resulted in the ion of 112.2 amu corresponding to the
nucleoside base, this is a typical fragmentation pattern for
nucleosides. The resulting transition of 268.2/112.2 was used
for a multi-reaction mode (MRM) detection method.
Chromatography consisted of a gradient system using
100% aqueous formic acid (0.1%) as eluent A and 40%
aqueous formic acid (0.1%) / 60% methanol for eluent B.
The gradient consisted of an initial 2 min hold at 96% A: 4%
B followed by an increase to 100% B over 10 min
(Phenomenex 100× 2.0 mm ODS3, 3 µm particle size
column maintained at 30 °C). Using the transition parameters
of 268.2/112.2 chromatography demonstrate retention times
of 0.6 min.
In vivo effect
In vivo testing of the compounds was performed using 5-FU
resistant HT-29 colon cancer cells, which were transplanted
subcutaneously into NMRI:nu/nu female mice [34]. This
model was chosen because it is more representative for
studying the anti-tumor effect related to humans. Treatment
of mice started at palpable tumor size and was performed in
a q4dx3 schedule. Mice were sacrificed when tumors
reached a size of more than 1 cm3. The tumor volumes of
treated tumors (T) were compared to those of controls (C),
which were PBS-treated. White blood cell counts (WBC)
were determined in peripheral blood, 4 days after initiation
of therapy with a Coulter Counter.
Results
Drug sensitivity
All compounds were active in FM3A/0 cells (Table 1). The
duplex, ETC-FdUrd, was active in FM3A/0, but 36-fold
less active in the TK deficient cells FM3A/TK−. This
indicates that TK may be important for the activity of ETC-
FdUrd, thus this drug is possibly cleaved to the FdUrd
nucleoside. The multidrug, ETC-L-FdUrd, was active in
FM3A/0, but not in FM3A/TK− cells. In this cell line, cell
growth by ETC-L-FdUrd was inhibited at a comparable
level as FdUrd itself. When cells were exposed to the
liposomal formulation of ETC-L-FdUrd, FM3A/TK− cells
became 60-fold more sensitive, compared to ETC-L-FdUrd.
However, FM3A/0 cells were less sensitive, compared to
ETC-L-FdUrd with a 3-fold increase in IC50. In FM3A/TK
−
cells, the liposomal ETC-L-FdUrd was only 4-fold less
active, indicating that TK was less important for the activity
of this drug, either by circumvention of active transport or
cleavage to ETC. Cells were exposed to the drugs for 72 h,
which requires relatively low levels of the drugs, which
remain below the Km for ENT mediated uptake, which is
Table 1 IC50 values (nM) of ETC-FdUrd and ETC-L-FdUrd
compared to their parent nucleoside analogues in sensitive and FdUrd
resistant cell lines
Growth inhibition (IC50 : nM)
Drugs FM3A/0 FM3A/TK− RF
ETC 1.6±0.2 4±0.2 2.5
FdUrd 3.2±0.1 4710±281 1472
ETC- FdUrd 2.2±1 79±70 36
ETC-L- FdUrd 7±2.7 4500±370 643
Liposome ETC-L- FdUrd 19.3±4.1 75±35 4
Cells were seeded in 96 wells plates and incubated with increasing
concentrations of drugs at 37 ºC under cell culture conditions. Cell
growth was determined after 72 h of incubation with the drug, using
the MTT assay (RF resistance factor). All values represent means of at
least 5 independent experiments±SEM
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usually >100 µM [35, 36]. At higher concentrations of
these drugs, passive diffusion will become more important.
Therefore we limited these experiments to a long exposure.
Transport into the cells
To determine whether the nucleoside transporter is circum-
vented by the multi- and duplex drugs, the inhibitor
dipyridamole was used (Table 2). When dipyridamole
decreases the drug cytotoxicity, these drugs are likely to
be dependent on the equilibrative nucleoside transporter to
enter the cells. As expected, in both cell lines the
cytotoxicity of both ETC and FdUrd decreased after
addition of dipyridamole. Since dipyridamole inhibited the
sensitivity to the parent drugs, ENT seems to be the most
important nucleoside transporter and the concentrative
nucleoside transporter (CNT) is probably not. Dipyridamole
did not protect against FdUrd cytotoxicity in FM3A/TK−
cells, which can be explained by the inactivity of FdUrd in
this cell line and the high concentration of FdUrd used in
the assay, at which the drug may enter the cells via passive
diffusion. The protection factor by dipyridamole against
ETC-L-FdUrd was very low, in contrast to that of ETC-
FdUrd of which the cytotoxicity was highly decreased. The
activity of the liposomal formulation was not influenced at
all by dipyridamole.
Extracellular cleavage of the drugs
Addition of nucleotidase and phosphatase inhibitors to the
cell cultures resulted in a 5.5–8.3 fold decreased cytotoxicity
of ETC-FdUrd (Table 2), indicating that ETC-FdUrd was
cleaved outside the cells. By contrast, the cytotoxicity of
ETC-L-FdUrd was hardly affected by nucleotidases or
phosphatases. Also, the cytotoxicity of the liposomal
formulation was hardly affected. Surprisingly, inhibition
of nucleotide breakdown also reduced the sensitivity to
ETC.
To demonstrate extracellular cleavage, we measured the
concentration of the prodrugs, ETC and FdUrd by HPLC
after 24 h incubation (Fig. 2). More than 60% of the parent
ETC-FdUrd drug was still present in the medium. The
concentrations of ETC and FdUrd were about 20 µM,
which was sufficient to exert cytotoxic effects (Fig. 2).
Extracellular ETC-L-FdUrd could not be detected with the
applied HPLC method, but ETC was found in the medium at
about 5 µM and FdUrd at concentrations below 1 µM. Similar
low concentrations of ETC were detected after incubation
with the liposomal formulation, whereas extracellular FdUrd
was hardly detected. This is in line with the findings that the
liposomal formulation was not affected by the inhibitors.
FdUMP accumulation
After exposure to FdUrd, FdUMP accumulated in FM3A/0
cells, and as expected hardly in FM3A/TK− cells (Table 3).
Exposure to ETC-FdUrd led to some accumulation of FdUMP
in FM3A/0 cells, but hardly in TK− cells. ETC-L-FdUrd
treatment resulted in a lower level of FdUMP accumulation
in FM3A/0 cells than FdUrd alone, but accumulation was
somewhat higher in FM3A/TK− cells. After exposure to the
ETC-L-FdUrd liposomes, FdUMP accumulated at comparable
levels in both FM3A/0 and TK− cells. These levels were
comparable to the FdUMP concentration after treatment with
ETC-L-FdUrd in FM3A/0 cells, indicating that this drug is at
least partially cleaved to FdUMP.
TS in situ activity
Since the direct effect of FdUMP accumulation is TS
inhibition, intracellular TS activity was measured after
treatment with the different drugs. As shown in Fig. 3, TS
activity was inhibited almost completely in FM3A/0 cells
after treatment with FdUrd. TS activity of FM3A/0 cells
was also inhibited effectively after treatment with both the
multi- and duplex drugs. The extent of TS inhibition was
Table 2 Level of cellular uptake dependent on nucleoside transporters and extracellullar degradation
Drugs Transporter inhibition (ratio) Extracellular degradation inhibition (ratio)
FM3A/0 FM3A/TK− FM3A/0 FM3A/TK−
ETC 8.6±0.1 9.9±1.7 9.2±2.1 9.7±1.7
FdUrd 10±0.9 1.2±0.6 1.0±0.1 2.0±0.4
ETC-FdUrd 8.3±2.1 9.3±2.3 5.5±3.9 8.3±1.7
ETC-L-FdUrd 1.4±0.6 2.0±0.8 1.4±0.1 2.0±0.6
Liposome ETC-L-FdUrd 1.0 1.0 1.0 1.0
Cells were seeded in 96 wells plates and incubated with increasing concentrations of drugs at 37ºC under cell culture conditions. Cell growth was
determined after 72 h of incubation with the drug, using the MTT assay. Transporter inhibition and extracellular degradation inhibition values
represent the protection factors defined as ratio of IC50 with inhibitors+drugs / IC50 without inhibitors + drugs. All values represent means of at
least 3 independent experiments±SEM
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FdUrd>ETC-FdUrd > ETC-L-FdUrd>liposomal ETC-L-
FdUrd, respectively. In FM3A/TK− cells, a lower extent of
TS inhibition was found. The degree of TS inhibition in
these cells was FdUrd>liposome ETC-L-FdUrd>ETC-
FdUrd > ETC-L-FdUrd.
In vivo sensitivity and accumulation of (phospho)
nucleosides
In order to determine whether the in vitro activity would
translate to an antitumor effect in vivo, we tested the drugs
in the human HT29 xenograft model. HT29 was one of the
cell lines most resistant to 5-FU in vitro [37], although this
resistance was not due to an increased TS expression. HT29
cells have a normal ENT expression [38], but this is most
likely not important for 5-FU since nucleoside transporters
do not play a role in base transport. A major difference
found in this cell line compared to other colon cancer cell
lines is its high expression of dUTPase, which can prevent
incorporation of FdUTP and dUTP into DNA (unpublished
results).
The in vitro IC50 concentrations in these cells of the
compounds are listed in Table 4. HT29 cells were 5-FU
resistant, but not cross-resistant to FdUrd and they were
more sensitive to ETC than to FdUrd. Both ETC-FdUrd
and ETC-L-FdUrd had similar activity as the parent
compounds. As summarized in Table 4, both i.v. and oral
administration of the multidrug were effective in the HT29-
xenograft, in contrast to the parental compounds, which
were orally inactive. Both ETC-FdUrd and ETC-L-FdUrd
were active after i.v. and oral treatment. Treatment with
either ETC-L-FdUrd or ETC-FdUrd did not result in any
haematological side effects. The antitumor effect was not
dose dependent (data not shown). As a control, mice were
treated with 5-FU, showing that HT-29 was resistant to this
agent.
After 2 h treatment with ETC-FdUrd, the ETC-nucleoside
and especially the ETC-nucleotides accumulated to a high
extent in the tumor tissue (Fig. 4). ETC derived from
ETC-L-FdUrd
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Fig. 2 Cleavage of ETC-L-FdUrd, ETC-FdUrd and the liposome of
ETC-L-FdUrd to the single nucleosides outside the cells after 24 h
incubation with 100 µM with the prodrugs. Uncleaved forms of ETC-L-
FdUrd and ETC-L-FdUrd liposome were not detectable by the applied
HPLC assay and are therefore not included in the graph. Values represent
means of 3–5 independent experiments±SEM
Table 3 Accumulation of FdUMP
Drugs FdUMP accumulation (fmol/106 cells)
FM3A/0 FM3A/TK−
ETC na na
FdUrd 16.4±3.42 0.23±0.21
ETC-FdUrd 1.5±0.01 0.07±0.03
ETC-L-FdUrd 1.0±0.1 0.71±0.11
Liposome ETC-L-FdUrd 1.0±0.1 1.2±0.04
FdUMP accumulation was determined after 24 h incubation with 0.05
µM drugs using a radioactive assay. Values represent means of three
independent experiments±SEM
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ETC-FdUrd accumulated in the liver tissue, although the
phosphate-forms were present at lower levels than in the
tumor tissue. After 4 h, ETC or ETC-nucleotides were hardly
present in either the tumor or the liver tissue (data not shown).
After 2 h treatment with the lipophilic ETC-L-FdUrd, both
ETC-nucleoside and the active nucleotide were detectable at
comparable levels in the tumor tissue. Both ETC and
ETC-nucleotides were present in the liver tissue, but to a
lower extent than after exposure to ETC-FdUrd. After 4 h, an
increase in ETC-nucleotides was detectable in the liver
tissue, however at lower levels than detected with ETC-
FdUrd (data not shown). In addition, the difference in the
presence of ETC and ETC-nucleotides between ETC-
FdUrd and ETC-L-FdUrd did not result in a difference in
anti-tumor response. This may be related to a more rapid
and direct action by ETC-FdUrd and a slower action by
the liphophilic ETC-L-FdUrd due to a slow release or
cleavage mechanism.
Discussion
In the present study, we show that combining several
advantages in one drug can be successful. The prodrugs
were designed with the primary aim to circumvent
decreased activation catalyzed by phosphorylation, while the
ETC-L-FdURD might also circumvent transport to some
extent. In vitro, ETC-FdUrd had the highest cytotoxic
activity, compared to ETC-L-FdUrd, however it did not
circumvent the nucleoside transporters, and it can be cleaved
extracellularly. The long lipophilic chain of ETC-L-FdUrd
can cause circumvention of the transporters, however
without leading to an increased cellular uptake. When
administered as a liposome, ETC-L-FdUrd was protected
from extracellular cleavage, underlining the advantage of the
use of liposomes as a delivery system.
To circumvent drug resistance, many types of new drugs
are under development, including several prodrugs. Some
Table 4 In vitro and in vivo activity of the drugs in human HT-29 xenograft model
compound In vitro activity In vivo activity
growth inhibition
(IC50 nM)
Route
administration
Dose
(mg/kg/inj)
Optimum
T/C (%)
WBC d14
(106/ml)
Evaluation
PBS – i.v. – – 7.5±1.9 –
5-FU 16400±5000† i.p. 30 80 8±2.7 Not effective
ETC 9.4±3.9 or. 10 77° 8.5±4.5 Not effective
FdUrd 56±19.9 i.p. 150 42* 4.5±2.2* Effective
FdUrd – or. 200 75 4.5±1* Not effective
ETC-FdUrd 5.4±0.9 i.v. 10 53 7.6±3.1 Effective
ETC-FdUrd – or. 40 47*° 7.6±1 Effective
ETC-L-FdUrd 7.3±1.9 i.v. 10 59* 7.7±1.6 Effective
ETC-L-FdUrd – or. 40 39* 6.2±0.1 Effective
In vitro values represent means of at least 3 independent experiments±SEM, * significant to PBS controls (p<0.05), ° 3/8 toxic deaths, † IC50 was
previously reported by Peters et al. [48] T/C is percent treated-control is calculated by dividing the median treated tumor weight by the median
control tumor weight. WBC is white blood cell count
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Fig. 4 ETC nucleoside and
nucleotide accumulation in
human HT-29-xenograft (tumor)
and liver tissues, 2 h after
administration of the ETC-
FdUrd and ETC-L-FdUrd.
ETC and ETC nucleotides
were measured with
LC-MS/MS detection.
Values represent means
of three independent
experiments±SEM
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examples of such prodrugs include a lipophilic derivative of
Ara-C (NOAC) and a heteronucleoside phosphate dimer
(NOAC-AraC), which have previously shown to exert
promising anticancer cytotoxicity [39] CP-4055 (Elacyt;
Clavis Pharma), an Ara-C elaidic acid derivative was
reported to be active in in vitro and in vivo models in which
Ara-C itself was inactive [40]. Elacyt can bypass the
nucleoside transporter, but requires dCK for activation [41].
Moreover, CP-4055 had a different metabolism and intra-
cellular accumulation than its parent compound, which
underlines the potency of lipophilic prodrugs [8]. A different
type of prodrug is FdUMP[10], a 10-mer of FdUMP, which
has shown a higher activity than 5-FU and FdUrd and also
has a higher activity in cells that overexpress TS [42, 43].
Other pronucleotide strategies have shown promising in vitro
results, however many have been unsuccessful in vivo [8].
These different prodrugs are either synthesized using the
nucleoside analogs or the mononucleotide of the parent
drug. The latter can then bypass the first phosphorylation
step. In order to combine the (pharmacologic and
therapeutic) advantages of two drugs, new multi- and
duplex drugs have been synthesized. The multidrug Ara-
C-L-FdUrd has previously shown strong antitumor effects
in vitro and could also overcome Ara-C and FdUrd
resistance [18]. However, Ara-C-L-FdUrd is cleaved
outside the cells to a high extent, limiting its cytotoxic
activity [19]. Extracellular cleavage of ETC-L-FdUrd was
found in the present study, indicating that the type of
lipophilic chain does not determine the fate of the drug.
Nucleoside analogs require phosphorylation to their active
forms, for FdUrd and ETC to FdUMP and ETCMP,
respectively. Our data indicate that both ETC-L-FdUrd and
ETC-FdUrd still require TK in order to be active, although
ETC-L-FdUrd to a lesser extent. FdUrd may therefore be the
most prominently released compound of this formulation.
Drug delivery systems, such as liposomes, lead to
improved chemical stability of drugs, enhanced accumulation
in tumors and decreased unwanted toxicity [44–46]. To
enhance cellular drug uptake, the multidrug ETC-L-FdUrd
was administered in a liposomal formulation. In vitro
cytotoxicity levels in FM3A/TK− cells indicated that this
formulation, when compared to ETC-L-FdUrd alone, is
probably cleaved inside the cells behind the phosphate
group, thereby circumventing TK. The decreased activity in
the wild type FM3A/0 cells may be explained by a decreased
permeability of the lipophilic drug because of accumulation
in the lipophilic cell membrane [47]. Both i.v. and oral
administration of ETC-L-FdUrd and ETC-FdUrd were
effective, in contrast to the parental analogues which were
inactive when administered orally. This underlines the
advantage that these drugs have over the parental nucleoside
analogs. ETC derived from ETC-L-FdUrd accumulated to a
high extent in the liver, which has been described in previous
studies using lipid drugs [8]. Optimized liposomal formula-
tions could result in a decreased uptake/accumulation in the
liver, such as polyethylene glycol (PEG) coated liposomes.
PEG liposomes have shown an increased accumulation at
tumor sites and have been evaluated in more than 20 clinical
trials [8]. These liposomes may increase the activity of the
multidrug used in this study. Moreover, these PEGylated
liposomes were reported in various studies to be able to
cross the blood brain barrier and to have an increased
delivery at brain-tumor sites [8, 47]. Combining the
attractive features of these drugs with lipophilic multidrugs
may result in a higher efficacy and potency to these drugs.
In conclusion, ETC-FdUrd was active but could not
completely circumvent resistance mechanisms, while ETC-
L-FdUrd could only bypass the nucleoside transporter.
The liposomal formulation of ETC-L-FdUrd showed the
best potency and could circumvent important resistance
mechanisms.
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